In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.

Bibliografske podrobnosti
Glavni avtor: Iva, Yesmine Akter
Drugi avtorji: Siam, Mohammad Kawsar Sharif
Format: Thesis
Jezik:English
Izdano: Brac University 2022
Teme:
Online dostop:http://hdl.handle.net/10361/17040
id 10361-17040
record_format dspace
spelling 10361-170402022-07-25T21:01:39Z In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2. Iva, Yesmine Akter Siam, Mohammad Kawsar Sharif Department of Pharmacy, Brac University SARS-CoV-2 Nucleocapsid protein Vaccine COVID-19 (Disease) This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021. Cataloged from PDF version of thesis report. Includes bibliographical references (pages 57-61). SARS-CoV-2 is a highly contagious and virulent coronavirus that has triggered a pandemic of acute respiratory disease (COVID-19), endangering human health. In this study the goal was to develop a peptide based multi-epitope sub-unit vaccine against SARS-Cov-2 that would utilize the Nucleocapsid protein (N). Antigen was selected based on two primary criteria: (1) Protein antigenicity. (2) Protein Functionality. At first the structural Nucleocapsid protein (N) was selected through proteomic screening for analysis by using Vipr database. Then Vaxijen 2.0 was used to test the antigenicity of our proteins at a minimal threshold of 0.5. This study used immunoinformatics approaches to discover B cell and T cell epitopes for SARS-CoV-2 Nucleocapsid protein (N), then estimated their antigenicity and corresponding relationships with human leukocyte antigen (HLA) alleles. All of the identified epitopes were then linked to the core antigen using the appropriate linkers to develop the vaccine formulation. Antigenicity of this developed vaccine was 0.5135. 11 B cell epitopes, 9 MHC class-I and 2 MHC class-II strong binding of Tcells epitopes were identified. Analyses of allergenicity, toxicity, and physicochemical properties confirmed the epitopes' specificity and selectivity. A PDB model of the final vaccine was created utilizing phyre2 server via homology modeling. From the biochemical analysis of PROTPARAM this research found that the vaccine and crude N protein had an aliphatic index of 48.47 and 52.53 respectively, while the unstability indexes are at 60.89 and 55.81 accordingly. Again, the vaccine construct's and crude N protein's Grand Average of Hydropathicity (GRAVY) values are -1.110 and -0.980 respectively. Then from Patchdock the best complex score of 18094 in the molecular docking algorithm based on shape complementarity principles under the area of 2671.30 square angstrom in the Atomic Contact Energy (ACE) of 464.89 was selected. An in-silico simulation study was conducted utilizing the C-immsim server to further verify the credibility of this vaccine's effectiveness, and as the result was unstable so addition of chaperones can help to stabilize the vaccine. Yesmine Akter Iva B. Pharmacy 2022-07-25T07:17:40Z 2022-07-25T07:17:40Z 2021 2021 Thesis ID 17346029 http://hdl.handle.net/10361/17040 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 61 pages application/pdf Brac University
institution Brac University
collection Institutional Repository
language English
topic SARS-CoV-2
Nucleocapsid protein
Vaccine
COVID-19 (Disease)
spellingShingle SARS-CoV-2
Nucleocapsid protein
Vaccine
COVID-19 (Disease)
Iva, Yesmine Akter
In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
description This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
author2 Siam, Mohammad Kawsar Sharif
author_facet Siam, Mohammad Kawsar Sharif
Iva, Yesmine Akter
format Thesis
author Iva, Yesmine Akter
author_sort Iva, Yesmine Akter
title In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
title_short In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
title_full In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
title_fullStr In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
title_full_unstemmed In-silico based vaccine development: targeting nucleocapsid protein of SARS-CoV-2.
title_sort in-silico based vaccine development: targeting nucleocapsid protein of sars-cov-2.
publisher Brac University
publishDate 2022
url http://hdl.handle.net/10361/17040
work_keys_str_mv AT ivayesmineakter insilicobasedvaccinedevelopmenttargetingnucleocapsidproteinofsarscov2
_version_ 1814307934628216832